HRMY
Harmony Biosciences Holdings, Inc.
Price Chart
Latest Quote
$34.45
+0.29 (+0.85%)
Current Price
| Previous Close | $34.16 |
| Open | $34.50 |
| Day High | $35.12 |
| Day Low | $34.33 |
| Volume | 825,944 |
Stock Information
| Shares Outstanding | 57.89M |
| Total Debt | $164.61M |
| Cash Equivalents | $640.92M |
| Revenue | $899.11M |
| Net Income | $145.62M |
| Sector | Healthcare |
| Industry | Biotechnology |
| Market Cap | $1.99B |
| P/E Ratio | 13.89 |
| EPS (TTM) | $2.48 |
| Exchange | NGM |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $1.52B |
| Sales | $899.11M |
| Income | $145.62M |
| Book/sh | $15.73 |
| Cash/sh | $11.07 |
| Employees | 293 |
Financial Ratios
| Quick Ratio | 3.45 |
| Current Ratio | 3.58 |
| Debt/Eq | 18.08 |
| EPS Growth TTM | -28.70% |
Returns & Margins
| ROA | 10.18% |
| ROE | 17.86% |
| Gross Margin | 76.55% |
| Operating Margin | 17.31% |
| Profit Margin | 16.20% |
Ownership
| Insider Ownership | 11.69% |
| Institutional Ownership | 103.47% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 6.17 |
| P/S | 2.22 |
| P/B | 2.19 |
Analyst Data
| Recommendation | none |
| Target Price | $44.36 |
Technical Indicators
| SMA20 | $33.13 |
| SMA50 | $31.76 |
| SMA200 | $32.25 |
| RSI | 64.21 |
| ATR | 1.1031 |
| Shares Float | 51.73M |
| Short Float | 13.73% |
| Short Ratio | 8.00 |
| Volatility | 0.97 |
| Rel Volume | 1.01 |
Performance History
| Week | +1.83% |
| Month | +14.26% |
| Quarter | +27.12% |
| 6 Months | -8.89% |
| YTD | -7.84% |
| Year | +7.89% |
| 3 Years | -5.02% |
| 5 Years | +9.37% |
| 10 Years | -6.92% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-24 | $34.45 | 825,944 |
| 2026-06-23 | $34.16 | 467,800 |
| 2026-06-22 | $33.43 | 654,200 |
| 2026-06-18 | $33.28 | 770,600 |
| 2026-06-17 | $33.77 | 626,900 |
| 2026-06-16 | $33.83 | 477,300 |
| 2026-06-15 | $34.18 | 985,800 |
| 2026-06-12 | $34.46 | 693,200 |
| 2026-06-11 | $35.20 | 820,500 |
| 2026-06-10 | $35.48 | 1,861,800 |
| 2026-06-09 | $34.10 | 1,091,500 |
| 2026-06-08 | $32.39 | 479,700 |
| 2026-06-05 | $32.20 | 462,300 |
| 2026-06-04 | $32.96 | 765,800 |
| 2026-06-03 | $32.10 | 1,009,300 |
| 2026-06-02 | $30.91 | 1,084,100 |
| 2026-06-01 | $31.81 | 752,300 |
| 2026-05-29 | $31.59 | 1,035,500 |
| 2026-05-28 | $31.49 | 899,700 |
| 2026-05-27 | $30.76 | 559,500 |
| 2026-05-26 | $30.09 | 699,200 |
About Harmony Biosciences Holdings, Inc.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States. The company offers WAKIX (pitolisant), a molecule with a novel mechanism of action for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. It also develops Pitolisant that is in Phase 3 clinical trial for the treatment of Prader-Willi Syndrome (PWS); in Phase 2 clinical trial to treat Myotonic Dystrophy (DM1); and is in Phase 2 clinical trials for the treatment of Pitolisant Gastro-Resistant (GR) and Pitolisant High-Dose (HD). In addition, the company's products under development include BP1.15205, an orexin 2 receptor agonist for the treatment of narcolepsy and other potential indications; and HBS-102, a melanin-concentrating hormone receptor type 1 (MCHR1) antagonist. Further, it develops ZYN-002 that is in a Phase 3 registrational trial for the treatment of Fragile X Syndrome; and 22q Deletion Syndrome, a disorder caused by a small missing piece on the long arm of the 22nd chromosome. Additionally, the company is developing EPX-100 (clemizole hydrochloride), a serotonin (5HT-2) receptor agonist to treat dravet syndrome and lenox-gastaut syndrome; EPX-200 (liquid formulation of lorcaserin), a selective 5HT-2C agonist to treat developmental and epileptic encephalopathies; CBS105 for the treatment-resistant narcolepsy; and CBS104 for refractory epilepsy. The company was formerly known as Harmony Biosciences II, Inc. and changed its name to Harmony Biosciences Holdings, Inc. in February 2020. Harmony Biosciences Holdings, Inc. was incorporated in 2017 and is headquartered in Plymouth Meeting, Pennsylvania.
đ° Latest News
Harmony Biosciences (HRMY) Stock Valuation After New Pitolisant Data And Reaffirmed Guidance
Simply Wall St. âĸ 2026-06-12T14:13:44Z
Is Harmony Biosciences Holdings, Inc. (HRMY) A Good Stock To Buy Now?
Insider Monkey âĸ 2026-06-11T14:18:24Z
Looking Back at Stock Picks Hyatt Hotels, Sensient Technologies, Harmony Biosciences. What the Charts Say.
Barrons.com âĸ 2026-06-04T05:14:00Z
Harmony Biosciences Holdings (HRMY): One of the Best Stocks to Buy According to AI
Insider Monkey âĸ 2026-06-01T17:02:25Z
A beaten-down biotech just lost a meaningful backer â should you care?
Motley Fool âĸ 2026-05-19T21:53:01Z
Investors Can Find Comfort In Harmony Biosciences Holdings' (NASDAQ:HRMY) Earnings Quality
Simply Wall St. âĸ 2026-05-14T13:45:52Z
Harmony Biosciences Holdings (HRMY) Announces Financial Results for Q1 2026
Insider Monkey âĸ 2026-05-12T21:28:04Z
Earnings Miss: Harmony Biosciences Holdings, Inc. Missed EPS By 21% And Analysts Are Revising Their Forecasts
Simply Wall St. âĸ 2026-05-11T16:28:34Z
ANIP Q1 Earnings & Sales Beat Estimates, '26 Outlook Raised
Zacks âĸ 2026-05-11T15:27:00Z
Harmony Biosciences Holdings (HRMY) Valuation After Q1 2026 Earnings Miss And Profitability Concerns
Simply Wall St. âĸ 2026-05-09T14:17:14Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $198,342,000 | $156,815,000 | $121,236,000 | $83,481,000 |
| Cost Of Revenue | $198,342,000 | $156,815,000 | $121,236,000 | $83,481,000 |
| Total Revenue | $868,453,000 | $714,734,000 | $582,022,000 | $437,855,000 |
| Operating Revenue | $868,453,000 | $714,734,000 | $582,022,000 | $437,855,000 |
| Expenses | ||||
| Interest Expense | $14,649,000 | $17,496,000 | $23,757,000 | $18,795,000 |
| Total Expenses | $659,984,000 | $523,908,000 | $389,992,000 | $317,669,000 |
| Other Income Expense | $-680,000 | $-68,000 | $-9,607,000 | $169,000 |
| Other Non Operating Income Expenses | $-680,000 | $-68,000 | $159,000 | $169,000 |
| Net Non Operating Interest Income Expense | $7,275,000 | $1,046,000 | $-9,027,000 | $-15,669,000 |
| Interest Expense Non Operating | $14,649,000 | $17,496,000 | $23,757,000 | $18,795,000 |
| Operating Expense | $461,642,000 | $367,093,000 | $268,756,000 | $234,188,000 |
| Selling And Marketing Expense | $119,512,000 | $110,916,000 | $97,404,000 | $79,285,000 |
| General And Administrative Expense | $152,536,000 | $110,352,000 | $95,289,000 | $84,017,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $158,687,000 | $145,493,000 | $128,853,000 | $181,468,000 |
| Net Interest Income | $7,275,000 | $1,046,000 | $-9,027,000 | $-15,669,000 |
| Interest Income | $21,924,000 | $18,542,000 | $14,730,000 | $3,126,000 |
| Normalized Income | $158,687,000 | $145,493,000 | $136,110,252 | $181,468,000 |
| Net Income From Continuing And Discontinued Operation | $158,687,000 | $145,493,000 | $128,853,000 | $181,468,000 |
| Total Operating Income As Reported | $208,469,000 | $190,826,000 | $192,030,000 | $120,186,000 |
| Net Income Common Stockholders | $158,687,000 | $145,493,000 | $128,853,000 | $181,468,000 |
| Net Income | $158,687,000 | $145,493,000 | $128,853,000 | $181,468,000 |
| Net Income Including Noncontrolling Interests | $158,687,000 | $145,493,000 | $128,853,000 | $181,468,000 |
| Net Income Continuous Operations | $158,687,000 | $145,493,000 | $128,853,000 | $181,468,000 |
| Pretax Income | $215,064,000 | $191,804,000 | $173,396,000 | $104,686,000 |
| Special Income Charges | $0 | $0 | $-9,766,000 | $0 |
| Interest Income Non Operating | $21,924,000 | $18,542,000 | $14,730,000 | $3,126,000 |
| Operating Income | $208,469,000 | $190,826,000 | $192,030,000 | $120,186,000 |
| Gross Profit | $670,111,000 | $557,919,000 | $460,786,000 | $354,374,000 |
| Per Share | ||||
| Diluted EPS | $2.71 | $2.51 | $2.13 | $2.97 |
| Basic EPS | $2.76 | $2.56 | $2.17 | $3.07 |
| Other | ||||
| Tax Effect Of Unusual Items | $0 | $0 | $-2,508,748 | $0 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $255,048,000 | $233,412,000 | $231,278,000 | $146,866,000 |
| Total Unusual Items | $0 | $0 | $-9,766,000 | $0 |
| Total Unusual Items Excluding Goodwill | $0 | $0 | $-9,766,000 | $0 |
| Reconciled Depreciation | $25,335,000 | $24,112,000 | $24,359,000 | $23,385,000 |
| EBITDA (Bullshit earnings) | $255,048,000 | $233,412,000 | $221,512,000 | $146,866,000 |
| EBIT | $229,713,000 | $209,300,000 | $197,153,000 | $123,481,000 |
| Diluted Average Shares | $58,544,570 | $57,869,915 | $60,372,397 | $61,097,045 |
| Basic Average Shares | $57,492,277 | $56,885,455 | $59,469,648 | $59,173,121 |
| Diluted NI Availto Com Stockholders | $158,687,000 | $145,493,000 | $128,853,000 | $181,468,000 |
| Tax Provision | $56,377,000 | $46,311,000 | $44,543,000 | $-76,782,000 |
| Research And Development | $189,594,000 | $145,825,000 | $76,063,000 | $70,886,000 |
| Selling General And Administration | $272,048,000 | $221,268,000 | $192,693,000 | $163,302,000 |
| Other Gand A | $152,536,000 | $110,352,000 | $95,289,000 | $84,017,000 |
| Other Special Charges | - | - | $9,766,000 | - |
Fetched: 2026-06-15
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $780,800,000 | $545,892,000 | $329,884,000 | $241,885,000 |
| Total Assets | $1,271,631,000 | $999,200,000 | $811,448,000 | $673,870,000 |
| Total Non Current Assets | $364,617,000 | $419,948,000 | $360,378,000 | $273,585,000 |
| Other Non Current Assets | $18,373,000 | $7,413,000 | $6,568,000 | $3,548,000 |
| Non Current Deferred Assets | $149,699,000 | $190,398,000 | $144,162,000 | $85,943,000 |
| Non Current Deferred Taxes Assets | $149,699,000 | $190,398,000 | $144,162,000 | $85,943,000 |
| Investmentin Financial Assets | $107,127,000 | $108,874,000 | $72,169,000 | $22,568,000 |
| Goodwill And Other Intangible Assets | $89,418,000 | $113,263,000 | $137,108,000 | $160,953,000 |
| Current Assets | $907,014,000 | $579,252,000 | $451,070,000 | $400,285,000 |
| Other Current Assets | $13,516,000 | $8,121,000 | $5,537,000 | $8,786,000 |
| Prepaid Assets | $16,014,000 | $13,714,000 | $12,570,000 | $9,347,000 |
| Inventory | $5,357,000 | $7,198,000 | $5,363,000 | $4,297,000 |
| Receivables | $96,787,000 | $83,033,000 | $74,140,000 | $54,740,000 |
| Accounts Receivable | $96,787,000 | $83,033,000 | $74,140,000 | $54,740,000 |
| Cash Cash Equivalents And Short Term Investments | $775,340,000 | $467,186,000 | $353,460,000 | $323,115,000 |
| Cash And Cash Equivalents | $752,502,000 | $453,001,000 | $311,660,000 | $243,784,000 |
| Other Intangible Assets | - | - | $137,108,000 | $160,953,000 |
| Debt | ||||
| Total Debt | $163,663,000 | $179,266,000 | $193,566,000 | $191,647,000 |
| Long Term Debt And Capital Lease Obligation | $143,663,000 | $163,016,000 | $178,566,000 | $189,647,000 |
| Long Term Debt | $143,663,000 | $163,016,000 | $178,566,000 | $189,647,000 |
| Current Debt And Capital Lease Obligation | $20,000,000 | $16,250,000 | $15,000,000 | $2,000,000 |
| Current Debt | $20,000,000 | $16,250,000 | $15,000,000 | $2,000,000 |
| Other Current Borrowings | $20,000,000 | $16,250,000 | $15,000,000 | $2,000,000 |
| Liabilities | ||||
| Total Liabilities Net Minority Interest | $401,413,000 | $340,045,000 | $344,456,000 | $271,032,000 |
| Total Non Current Liabilities Net Minority Interest | $149,281,000 | $164,963,000 | $180,675,000 | $192,148,000 |
| Other Non Current Liabilities | $5,618,000 | $1,947,000 | $2,109,000 | $2,501,000 |
| Current Liabilities | $252,132,000 | $175,082,000 | $163,781,000 | $78,884,000 |
| Other Current Liabilities | $4,957,000 | $5,672,000 | $7,810,000 | $1,624,000 |
| Payables And Accrued Expenses | $208,732,000 | $134,384,000 | $117,224,000 | $63,728,000 |
| Interest Payable | $2,151,000 | $2,834,000 | $3,354,000 | $3,286,000 |
| Payables | $17,693,000 | $13,744,000 | $17,730,000 | $3,786,000 |
| Accounts Payable | $17,693,000 | $13,744,000 | $17,730,000 | $3,786,000 |
| Equity | ||||
| Common Stock Equity | $870,218,000 | $659,155,000 | $466,992,000 | $402,838,000 |
| Total Equity Gross Minority Interest | $870,218,000 | $659,155,000 | $466,992,000 | $402,838,000 |
| Stockholders Equity | $870,218,000 | $659,155,000 | $466,992,000 | $402,838,000 |
| Gains Losses Not Affecting Retained Earnings | $346,000 | $66,000 | $2,000 | $-151,000 |
| Other Equity Adjustments | $346,000 | $66,000 | $2,000 | $-151,000 |
| Retained Earnings | $160,903,000 | $2,216,000 | $-143,277,000 | $-272,130,000 |
| Other | ||||
| Ordinary Shares Number | $57,726,170 | $57,144,887 | $56,769,081 | $59,615,731 |
| Share Issued | $57,726,170 | $57,144,887 | $56,769,081 | $59,615,731 |
| Tangible Book Value | $780,800,000 | $545,892,000 | $329,884,000 | $241,885,000 |
| Invested Capital | $1,033,881,000 | $838,421,000 | $660,558,000 | $594,485,000 |
| Working Capital | $654,882,000 | $404,170,000 | $287,289,000 | $321,401,000 |
| Total Capitalization | $1,013,881,000 | $822,171,000 | $645,558,000 | $592,485,000 |
| Additional Paid In Capital | $708,968,000 | $656,872,000 | $610,266,000 | $675,118,000 |
| Capital Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Common Stock | $1,000 | $1,000 | $1,000 | $1,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $18,443,000 | $18,776,000 | $23,747,000 | $11,532,000 |
| Current Accrued Expenses | $191,039,000 | $120,640,000 | $99,494,000 | $59,942,000 |
| Investments And Advances | $107,127,000 | $108,874,000 | $72,169,000 | $22,568,000 |
| Available For Sale Securities | $107,127,000 | $108,874,000 | $72,169,000 | $22,568,000 |
| Inventories Adjustments Allowances | $-164,000 | $0 | $0 | $-619,000 |
| Finished Goods | $2,636,000 | $2,765,000 | $2,283,000 | $2,565,000 |
| Work In Process | $2,885,000 | $3,489,000 | $2,020,000 | $1,513,000 |
| Raw Materials | $0 | $944,000 | $1,060,000 | $838,000 |
| Other Short Term Investments | $22,838,000 | $14,185,000 | $41,800,000 | $79,331,000 |
| Net PPE | - | $1,257,000 | $371,000 | $573,000 |
| Treasury Shares Number | - | - | $0 | - |
| Preferred Stock | - | - | - | $0 |
Fetched: 2026-06-15
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $347,889,000 | $218,668,000 | $219,075,000 | $144,294,000 |
| Operating Activities | ||||
| Operating Cash Flow | $348,199,000 | $219,821,000 | $219,387,000 | $144,466,000 |
| Cash Flow From Continuing Operating Activities | $348,199,000 | $219,821,000 | $219,387,000 | $144,466,000 |
| Operating Gains Losses | - | - | $9,766,000 | - |
| Investing Activities | ||||
| Capital Expenditure | $-310,000 | $-1,153,000 | $-312,000 | $-172,000 |
| Investing Cash Flow | $-39,649,000 | $-67,484,000 | $-46,439,000 | $-141,832,000 |
| Cash Flow From Continuing Investing Activities | $-39,649,000 | $-67,484,000 | $-46,439,000 | $-141,832,000 |
| Net Other Investing Changes | $-15,000,000 | $-25,500,000 | - | $-40,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $0 | $-100,000,000 | $0 |
| Financing Cash Flow | $-9,049,000 | $-10,996,000 | $-105,552,000 | $6,841,000 |
| Cash Flow From Continuing Financing Activities | $-9,049,000 | $-10,996,000 | $-105,552,000 | $6,841,000 |
| Net Other Financing Charges | $-3,004,000 | $-2,497,000 | $-9,357,000 | - |
| Net Common Stock Issuance | $0 | $0 | $-100,000,000 | $0 |
| Issuance Of Capital Stock | - | - | $0 | $0 |
| Common Stock Issuance | - | - | $0 | $0 |
| Net Preferred Stock Issuance | - | - | - | - |
| Preferred Stock Issuance | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-16,250,000 | $-15,000,000 | $-201,250,000 | $-2,000,000 |
| Issuance Of Debt | $0 | $0 | $200,000,000 | $0 |
| Interest Paid Supplemental Data | $14,685,000 | $17,317,000 | $20,051,000 | $16,364,000 |
| Income Tax Paid Supplemental Data | $19,820,000 | $79,635,000 | $48,233,000 | $12,645,000 |
| End Cash Position | $752,772,000 | $453,271,000 | $311,930,000 | $244,534,000 |
| Beginning Cash Position | $453,271,000 | $311,930,000 | $244,534,000 | $235,059,000 |
| Changes In Cash | $299,501,000 | $141,341,000 | $67,396,000 | $9,475,000 |
| Proceeds From Stock Option Exercised | $10,205,000 | $6,501,000 | $5,055,000 | $8,841,000 |
| Common Stock Payments | $0 | $0 | $-100,000,000 | $0 |
| Net Issuance Payments Of Debt | $-16,250,000 | $-15,000,000 | $-1,250,000 | $-2,000,000 |
| Net Long Term Debt Issuance | $-16,250,000 | $-15,000,000 | $-1,250,000 | $-2,000,000 |
| Long Term Debt Payments | $-16,250,000 | $-15,000,000 | $-201,250,000 | $-2,000,000 |
| Long Term Debt Issuance | $0 | $0 | $200,000,000 | $0 |
| Net Investment Purchase And Sale | $-5,089,000 | $-6,762,000 | $-9,160,000 | $-101,660,000 |
| Sale Of Investment | $81,062,000 | $98,527,000 | $118,309,000 | $9,069,000 |
| Purchase Of Investment | $-86,151,000 | $-105,289,000 | $-127,469,000 | $-110,729,000 |
| Net Business Purchase And Sale | $-19,250,000 | $-34,069,000 | $-36,967,000 | $0 |
| Purchase Of Business | $-19,250,000 | $-34,069,000 | $-36,967,000 | $0 |
| Net PPE Purchase And Sale | $-310,000 | $-1,153,000 | $-312,000 | $-172,000 |
| Purchase Of PPE | $-310,000 | $-1,153,000 | $-312,000 | $-172,000 |
| Change In Working Capital | $91,817,000 | $-7,321,000 | $35,035,000 | $-4,106,000 |
| Change In Other Current Liabilities | $67,994,000 | $11,799,000 | $46,478,000 | $20,419,000 |
| Change In Payables And Accrued Expense | $3,949,000 | $-5,384,000 | $8,949,000 | $2,785,000 |
| Change In Payable | $3,949,000 | $-5,384,000 | $8,949,000 | $2,785,000 |
| Change In Account Payable | $3,949,000 | $-5,384,000 | $8,949,000 | $2,785,000 |
| Change In Prepaid Assets | $31,787,000 | $-3,008,000 | $74,000 | $-7,548,000 |
| Change In Inventory | $1,841,000 | $-1,835,000 | $-1,066,000 | $135,000 |
| Change In Receivables | $-13,754,000 | $-8,893,000 | $-19,400,000 | $-19,897,000 |
| Changes In Account Receivables | $-13,754,000 | $-8,893,000 | $-19,400,000 | $-19,897,000 |
| Other Non Cash Items | $36,287,000 | $46,494,000 | $5,803,000 | $3,921,000 |
| Stock Based Compensation | $44,895,000 | $42,602,000 | $31,705,000 | $26,173,000 |
| Amortization Of Securities | $-1,521,000 | $-2,261,000 | $-2,715,000 | $-432,000 |
| Deferred Tax | $-7,301,000 | $-29,298,000 | $-13,419,000 | $-85,943,000 |
| Deferred Income Tax | $-7,301,000 | $-29,298,000 | $-13,419,000 | $-85,943,000 |
| Depreciation Amortization Depletion | $25,335,000 | $24,112,000 | $24,359,000 | $23,385,000 |
| Depreciation And Amortization | $25,335,000 | $24,112,000 | $24,359,000 | $23,385,000 |
| Amortization Cash Flow | $23,845,000 | $23,845,000 | $23,845,000 | $22,966,000 |
| Amortization Of Intangibles | $23,845,000 | $23,845,000 | $23,845,000 | $22,966,000 |
| Depreciation | $1,490,000 | $267,000 | $514,000 | $419,000 |
| Net Income From Continuing Operations | $158,687,000 | $145,493,000 | $128,853,000 | $181,468,000 |
| Net Intangibles Purchase And Sale | - | - | $0 | $-40,000,000 |
| Purchase Of Intangibles | - | - | $0 | $-40,000,000 |
| Change In Accrued Expense | - | - | $46,479,000 | $20,570,000 |
| Change In Other Current Assets | - | - | - | - |
Fetched: 2026-06-15